Skip to main content

Advertisement

SpringerLink
Log in

Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report

  • Case Report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

A 67-year-old man with metastatic prostate cancer was treated with leuprorelin and enzalutamide, but presented radiographic progression after 1 year. Although docetaxel chemotherapy was initiated, liver metastasis appeared with elevation of nerve-specific enolase in serum. Pathological findings of needle biopsy of lymph node metastasis in the right inguinal region showed neuroendocrine carcinoma. FoundationOne CDx® using a biopsy sample of the prostate at initial diagnosis detected the BRCA1 mutation (deletion of intron 3–7), but BRACAnalysis® test revealed no BRCA mutation in germline. Then, olaparib treatment was initiated, resulting in remarkable remission of tumors, but comorbidity with interstitial pneumonia. This case suggested that olaparib could be effective for neuroendocrine prostate cancer with BRCA1 gene mutation, but may cause interstitial pneumonia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The data in this report are available on request from the corresponding author.

References

  1. Nadal R, Schweizer M, Kryvenko ON et al (2014) Small cell carcinoma of the prostate. Nat Rev Urol 11(4):213–219. https://doi.org/10.1038/nrurol.2014.21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang HT, Yao YH, Li BG et al (2014) Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol 32(30):3383–3390. https://doi.org/10.1200/JCO.2013.54.3553

    Article  PubMed  Google Scholar 

  3. Okasho K, Ogawa O, Akamatsu S (2021) Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Transl Androl Urol 10(10):3953–3962. https://doi.org/10.21037/tau-20-1131

    Article  PubMed  PubMed Central  Google Scholar 

  4. de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091–2102. https://doi.org/10.1056/NEJMoa1911440

    Article  PubMed  Google Scholar 

  5. National cancer center Japan: Projected Cancer Statistics. https://ganjoho.jp/reg_stat/statistics/stat/short_pred_en.html [Accessed on 21 Sep. 2022]

  6. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2):276–308. https://doi.org/10.1210/er.2002-0032

    Article  CAS  PubMed  Google Scholar 

  7. Ryan CJ, Tindall DJ (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29(27):3651–3658. https://doi.org/10.1200/JCO.2011.35.2005

    Article  CAS  PubMed  Google Scholar 

  8. Galletti G, Leach BI, Lam L et al (2017) Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev 57:16–27. https://doi.org/10.1016/j.ctrv.2017.04.008

    Article  CAS  PubMed  Google Scholar 

  9. Vlachostergious PJ, Puca L, Beltran H (2017) Emerging variants of castration-resistant prostate cancer. Curr Oncol Rep 19(5):32. https://doi.org/10.1007/s11912-017-0593-6

    Article  CAS  Google Scholar 

  10. Aggarwal R, Huang J, Alumkal JJ et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36(24):2492–2503. https://doi.org/10.1200/JCO.2017.77.6880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025. https://doi.org/10.1016/j.cell.2015.10.025

    Article  CAS  Google Scholar 

  12. Tetu B, Ro JY, Ayala AG et al (1987) Small cell carcinoma of the prostate Part I A clinicopathologic study of 20 cases. Cancer 59(10):1803–1809. https://doi.org/10.1002/1097-0142(19870515)59:10%3c1803::aid-cncr2820591019%3e3.0.co;2-x

    Article  CAS  PubMed  Google Scholar 

  13. Yamada Y, Beltran H (2021) Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep 23(2):15. https://doi.org/10.1007/s11912-020-01003-9

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cooper CS, Eeles R, Wedge DC et al (2015) Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 47(4):367–372. https://doi.org/10.1038/ng.3221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Boutros PC, Fraser M, Harding NJ et al (2015) Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47(7):736–745. https://doi.org/10.1038/ng.3315

    Article  CAS  PubMed  Google Scholar 

  16. Fraser M, Sabelnykova VY, Yamaguchi TN et al (2017) Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541(7637):359–364. https://doi.org/10.1038/nature20788

    Article  CAS  PubMed  Google Scholar 

  17. Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16(11):645–654. https://doi.org/10.1038/s41585-019-0237-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228. https://doi.org/10.1016/j.cell.2015.06.053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Beltran H, Oromendia C, Danila DC et al (2019) A phase II trial of the Aurora Kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 25(1):43–51. https://doi.org/10.1158/1078-0432.CCR-18-1912

    Article  CAS  PubMed  Google Scholar 

  20. Symonds L, Konnick E, Vakar-Lopez F et al (2022) BRCA2 alternations in neuroendocrine/small-cell carcinoma prostate cancer: a case series. JCO Precis Oncol 6:e2200091. https://doi.org/10.1200/PO.22.00091

    Article  PubMed  Google Scholar 

  21. Lozano R, Castro E, Aragón IM et al (2021) Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer 124(3):552–563. https://doi.org/10.1038/s41416-020-01114-x

    Article  CAS  PubMed  Google Scholar 

  22. Momozawa Y, Iwasaki Y, Parsons MT et al (2018) Germline pathogenic variants of 11 breast cancer genes in 7051 Japanese patients and 11,241 controls. Nat Commun 9(1):4083. https://doi.org/10.1038/s41467-018-06581-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Enomoto T, Aoki D, Hattori K et al (2019) The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer 29(6):1043–1049. https://doi.org/10.1136/ijgc-2019-000384

    Article  PubMed  Google Scholar 

  24. Momozawa Y, Iwasaki Y, Hirata M et al (2020) Germline pathogenic variants in 7636 Japanese patients with prostate cancer and 12 366 controls. J Natl Cancer Inst 112(4):369–376. https://doi.org/10.1093/jnci/djz124

    Article  CAS  PubMed  Google Scholar 

  25. Hussain M, Mateo J, Fizazi K et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357. https://doi.org/10.1056/NEJMoa2022485

    Article  CAS  PubMed  Google Scholar 

  26. Pandya D, Shah M, Kaplan F et al (2021) Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Cold Spring Harb Mol Case Stud 7(1):a005801. https://doi.org/10.1101/mcs.a005801

    Article  PubMed  PubMed Central  Google Scholar 

  27. Turina CB, Coleman DJ, Thomas GV et al (2019) Molecular testing identifies determinants of exceptional response and guides precision therapy in a patient with lethal, treatment-emergent neuroendocrine prostate cancer. Cureus 11(7):e5197. https://doi.org/10.7759/cureus.5197

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wu Y, Gao Y, Dou X et al (2020) Metastatic castration-resistant prostate cancer with neuroendocrine transformation and BRCA 1 germ-line mutation: a case report and literature review. Onco Targets Ther 13:8049–8054. https://doi.org/10.2147/OTT.S264347

    Article  PubMed  PubMed Central  Google Scholar 

  29. Suzuki H, Oshino T, Hagio K et al (2020) Interstitial pneumonia caused by olaparib during treatment of breast cancer-a case report. Gan To Kagaku Ryoho 47(9):1351–1353

    PubMed  Google Scholar 

  30. Shu Y, He X, Liu Y et al (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Epidemiology 14:789–802. https://doi.org/10.2147/CLEP.S365513

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812–8582, Japan

    Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi & Masatoshi Eto

  2. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Dai Takamatsu & Yoshinao Oda

Authors
  1. Masashi Kaitsumaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaki Shiota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dai Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leandro Blas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junichi Inokuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshinao Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masatoshi Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Shiota.

Ethics declarations

Conflict of interest

Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, and Sanofi. Masatoshi Eto received honoraria from Takeda Pharmaceutical, and Janssen Pharmaceutical, and research funding support from Sanofi, Bayer Yakuhin, Astellas Pharma, and Takeda Pharmaceutical.

Ethical approval

This study was approved by the Institutional Ethics Committee (Approval No. 2021–123).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaitsumaru, M., Shiota, M., Takamatsu, D. et al. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. Int Canc Conf J 12, 131–136 (2023). https://doi.org/10.1007/s13691-022-00592-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-022-00592-5

Keywords

Search

Navigation